DNMT3B

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin. Covadonga Pañeda, Ph.D., the Company's Chief Operating Officer, will give a presentation at the conference titled, "Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles”. In addition, she will participate in the panel discussion on “Tissue specific targeting of mRNA to increase therapeutic efficacy.” "There is a strong and growing interest in the use of mRNA for highly targeted treatment of a broad range of human diseases, based on the unique ability of mRNA to promote expression of specific proteins,” Dr. Pañeda commented. “However, even the most powerful mRNA therapeutic is useless if it is not delivered safely and effectively into target cells, which has remained one of the key challenges for non-hepatic targets to date. Thanks to our SemaPhore platform we are able to deliver therapeutic mRNA, in an efficient and safe manner, to tissues harboring a tumor or suffering from acute or chronic inflammation, restricting the therapeutic effect of the drug to the site where it is needed." SemaPhore™, Altamira’s peptide-based delivery platform for mRNA, has been successfully tested so far in vivo in models of osteoarthritis (WNT16, DNMT3B), atherosclerosis (p27Kip1), aortic aneurysm (SOD2), and tumor microenvironment (ZBTB46). About Altamira Therapeutics Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com Forward-Looking Statements This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of strategic transactions, including licensing or partnering, with respect to Altamira’s legacy assets, Altamira’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2022, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

导读：胆管癌(CCA)是指与预后不良相关的一系列恶性肿瘤。目前，手术切除是治疗CCA的唯一方法。可用的全身治疗仅限于吉西他滨加顺铂;然而，这种治疗本质上是治标不治本的。因此，仍然需要探索新的有效的治疗靶点来干预CCA。近日，华中科技大学研究人员在权威期刊《Clinical And Translational Medicine》上发表了题为“Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression”的研究论文，本研究中，研究人员分析了EZH2在CCA中的表达和患者预后。通过异种移植模型和原发性CCA小鼠模型，检测并验证了基因敲低和过表达后CCA细胞的增殖、迁移和侵袭能力。针对DNA甲基化，在EZH2和SUZ12敲除的CCA细胞中进行了基于RNA测序的转录组学分析。数据强烈表明，靶向PRC2可促进SFRP1的表达，从而抑制CCA的进展。https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/full/10.1002/ctm2.1502研究背景 01 胆管癌(CCA)是指与预后不良相关的一系列恶性肿瘤。在全球许多国家，CCA的发病率呈上升趋势。目前，手术切除是唯一有效的治疗选择。然而，不幸的是，在诊断时，几乎三分之二的CCA患者已经患有晚期疾病。此外，即使在切除后，仍有相当比例的患者(68%至86%)经历局部或远处肿瘤复发。目前，CCA患者可用的全身治疗仅限于吉西他滨+顺铂，这仍然是标准的化疗选择。然而，这种治疗是治标不治本的，收效甚微。因此，仍然需要探索新的药物靶点来进行CCA治疗干预。多梳抑制复合物2 (PRC2)由EZH2、SUZ12和EED三个核心因子组成，作为染色质相关的甲基转移酶，催化组蛋白H3上赖氨酸27的单、二和三甲基化(H3K27)。PRC2是唯一在H3K27上具有活性的甲基转移酶，EZH2作为PRC2的催化亚基，但需要EED和SUZ12的物理存在才能产生催化活性。多项研究证明，PRC2在血液学和实体肿瘤中都具有致癌特性。此外，其亚基在前列腺癌、乳腺癌、肺癌、膀胱癌和胰腺癌等多种癌症中均存在显著失调。PRC2的作用包括通过多种机制促进癌症进展。首先，PRC2催化赖氨酸27处组蛋白H3的甲基化，即H3K27me3，它与癌症转移和生长有关。此外，EZH2具有非组蛋白甲基化酶催化活性，这也有助于癌症的进展。目前还没有足够的证据来确定PRC2是否有助于CCA的进展并在CCA中发挥作用。研究进展 02 大量研究揭示了PRC2在癌症进展中的重要作用，并表明它可能是一个有用的治疗靶点。从PRC2的分子功能来看，它在肿瘤细胞的起源和肿瘤的发展过程中建立了一些基因的抑制状态。EZH2是PRC2复合体的一个酶亚基，通过其催化和非催化活性在肿瘤发展中发挥重要作用。靶向EZH2治疗肿瘤是当前涉及肿瘤免疫、肿瘤代谢和肿瘤耐药的研究课题。在本研究中，研究人员从临床数据、CCA细胞、异种移植小鼠和原代CCA模型中证实了PRC2的核心催化亚基EZH2的致癌作用。研究人员发现，敲除PRC2的三个核心亚基(EZH2、SUZ12和EED)以及EZH2抑制剂GSK126、GSK343，会损害PRC2特异性H3K27me3的催化功能，并进一步导致SFRP1启动子的DNA低甲基化和SFRP1的转录激活。研究人员之前证实了SFRP1是CCA中DNA甲基化转录的高度调控基因。研究表明PRC2和DNA甲基化共同保护癌症中的肿瘤细胞。事实上，EZH2作为募集DNA甲基转移酶的平台，是某些基因启动子中DNA甲基化所必需的。在一些肿瘤中，EZH2可以募集DNA甲基转移酶到相关基因的启动子区域，促进DNA甲基化。研究人员也证实了组蛋白修饰的沉积不足以抑制靶基因的转录。其原因是靶基因的表达受到H3K27me3和DNA甲基化的二价表观遗传调控。从本研究结果来看，敲除CCA中PRC2的三个亚基之一会导致其他两个亚基的蛋白水平降低，这两个亚基也会损害PRC2的H3K27me3催化功能。相反，SUZ12的转录后修饰通过增强PRC2功能促进催化和抑制靶基因。针对EZH2，目前出现了多种抑制剂，包括针对EZH2特异性H3K27me3催化活性的抑制剂和降低EZH2或EED蛋白水平的抑制剂。包括地西他滨在内的DNA甲基转移酶抑制剂对DNMT3a、DNMT3b和DNMT1具有显著的抑制作用，已被批准用于治疗血液肿瘤和向实体肿瘤扩展。然而，它非特异性地降低全基因组甲基化并导致基因组不稳定，这反过来增加了肿瘤增殖和侵袭的风险。因此，一种新的抗癌思路是通过EZH2抑制剂靶向prc2介导的DNA超甲基化引起的肿瘤进展。在体外和体内，抑制EZH2可破坏胆管癌(CCA)的进展研究结论 03 本研究为PRC2在CCA中的作用和潜在机制提供了深入的见解。它主要针对PRC2介导的H3K27me3和DNA超甲基化，导致SFPR1的二价启动子表观遗传沉默，抑制CCA的进展。这些发现表明，靶向PRC2，例如使用EZH2抑制剂，可能是开发CCA抗癌药物的一种有希望的方法。参考资料：https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/full/10.1002/ctm2.1502识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical company initiated for OligoPhore™ platform Partnering discussions for legacy assets progressing with conclusion of clinical development program and opening of IND as key milestones for Bentrio® and AM-125 Significant strengthening of shareholders’ equity and balance sheet Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results. "We continue progressing with the strategic repositioning toward becoming a leading provider of innovative RNA delivery technology," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO. "We have achieved great strides in enhancing awareness and visibility of our OligoPhore™ / SemaPhore™ platforms for extrahepatic RNA delivery and efficient endosomal release; as a result, we recently entered into our first collaboration with a biopharmaceutical company. We look forward to working with Heqet Therapeutics, in the framework of this first collaboration, on their mission to develop treatments for cardiac regeneration, applying RNA with our OligoPhore™ platform. We are excited to see interest in our technology growing steadily and remain confident about the potential to develop further partnerships with biopharmaceutical companies. "Meanwhile, we have reached important clinical and regulatory milestones in our legacy programs in OTC consumer health and inner ear therapeutics," Mr. Meyer added. "Our clinical trial with Bentrio in seasonal allergic rhinitis met the primary endpoint, adding further to our set of compelling efficacy data. In addition, the FDA cleared an IND for our AM-125 investigational drug in acute vestibular syndrome. These milestones are important elements in our ongoing partnering discussions.” “As part of our strategic pivot, we have adapted our organization, downsized activities especially in clinical development, and reallocated resources from our legacy programs towards our RNA delivery projects. This has allowed for a significant reduction in expense levels. At the same time, we have managed to significantly improve our shareholders’ equity position while reducing financial liabilities.” RNA Delivery Technology Altamira has continued to make progress with the further development of the RNA delivery technology around its OligoPhore™ / SemaPhore™ platforms, which are based on a patented peptide for delivery of RNA in nanoparticles to extrahepatic tissues and efficient endosomal release inside target cells. Two in vivo studies performed by independent research groups at Washington University School of Medicine (St. Louis, MO) using our SemaPhore™ platform provided further external validation of the technology. In a preprint, one research group presented animal data showing restriction of tumor growth with nanoparticles based on SemaPhore™ and ZBTB46 mRNA. Enforced ZBTB46 expression following treatment with the nanoparticles resulted in an immunostimulatory tumor microenvironment and restricted tumor growth. The effect was significantly potentiated when the treatment was combined with anti-PD1 immune checkpoint inhibition, suggesting that ZBTB46 mRNA delivered by SemaPhore™ nanoparticles could be an effective adjuvant therapy with immunotherapy in cancer management. Meanwhile, the other research group presented results from an animal study with DNMT3B mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology at the Osteoarthritis Research Society International World Congress in Denver (CO). Local (intra-articular) administration of the nanoparticles to mice with meniscal injury resulted in strong induction of DNMT3B protein as well as significantly reduced bone sclerosis, cartilage degeneration, and synovitis (inflammation of the connective tissue lining the inside of a joint capsule). Functional studies showed significantly decreased pain sensitivity and improved weight bearing in active treated mice compared to controls. At the same time, the Company advanced work on its two flagship development programs AM-401, for the treatment of KRAS-driven tumors, and AM-411, for the treatment of rheumatoid arthritis; targeting NF-kB, aiming for an IND submission in 2024. Altamira plans to out-license the two programs either following the IND or after a Phase 1 clinical trial at the latest. Importantly, the Company filed a provisional patent application relating to single polyvalent siRNA sequences which as part of AM-401 can target different KRAS mutations (polyKRASmut). If granted, the patent would extend IP coverage for the program to 2043. In line with the Company’s strategy of leveraging the OligoPhore™/SemaPhore™ through out-licensing and partnering rather than commercializing its own drug products, Altamira has significantly expanded its business development activities. This includes the engagement of Maria Grunwald, PhD, MBA, a highly experienced business developer based in Boston, as Senior Business Advisor. On July 5, 2023 the Company announced that it entered into a collaboration and option agreement with Heqet Therapeutics s.r.l. (“Heqet”), a biotech spin-out from King’s College London. Under the terms of the agreement, Heqet will test nanoparticles based on Altamira’s OligoPhore™ delivery platform and comprising certain non-coding RNAs (ncRNAs) in the regeneration of damaged heart tissue following myocardial infarction in animal models. Upon successful conclusion of the experiments, Heqet will, under certain conditions, have the option to negotiate with Altamira for a license to use the Company’s technology and intellectual property to translate its findings into the development of therapeutics for cardiac regeneration. Bentrio® Nasal Spray On May 24, 2023, Altamira announced positive results from the randomized controlled NASAR clinical trial evaluating Bentrio® nasal spray in patients with seasonal allergic rhinitis (SAR). The NASAR trial enrolled 100 SAR patients in Australia who were randomized at a 1:1 ratio to receive either Bentrio® or saline nasal spray for two weeks via self-administration three times per day, or as needed. For eligibility, patients had to have a baseline reflective Total Nasal Symptom Score (rTNSS) of at least 5 points out of 12, referring to the worst level of nasal congestion, sneezing, nasal itching, and rhinorrhea (runny nose) within the past 24 hours averaged over a one-week treatment-free run-in period. The primary efficacy endpoint was defined as the difference in the average rTNSS over the subsequent 2-week treatment period between Bentrio® and saline nasal spray, the current standard of care in drug-free SAR management. The rTNSS decreased in the Bentrio® group from 6.9 points in the pre-treatment period to an average of 5.0 points over the 14-day treatment period (i.e. -1.9 points), while the saline spray group showed a decrease from 6.9 to 6.2 points (i.e. -0.8 points). The reduction in nasal symptoms conferred by Bentrio® was thus 2.4 times larger than with saline nasal spray. The difference in rTNSS reduction of 1.1 points in favor of Bentrio® was statistically significant in the ANCOVA model (LSmeans; p = 0.012; 95% confidence interval -2.0 to -0.3), and the study thus met the primary efficacy endpoint. 63.3% of Bentrio®-treated study participants rated treatment efficacy as either good or very good vs. 29.2% of saline-treated participants. 73.5% of Bentrio®-treated study participants rated tolerability of the treatment as either good or very good vs. 85.5% of saline-treated participants. The Company expects to release further results from the NASAR trial shortly and to submit an article for publication in a peer-reviewed medical journal. The data read-out from the NASAR trial completes the Bentrio® development program in allergic rhinitis. Previous clinical trials demonstrated the safety, tolerability and efficacy of Bentrio in patients exposed to grass pollen or house dust mites under controlled conditions and the extended nasal residence time of more than three hours in human volunteers. The accumulated data suggest that Bentrio®, based on a drug-free and preservative-free formulation, can help to effectively reduce the most common symptoms of allergic rhinitis similar to the reduction observed in response to medicated nasal sprays, but without the tolerability issues frequently experienced with the use of such sprays. On July 20, 2023, Altamira announced that it entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio® in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio® in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on. Discussions with potential marketing and distribution partners for the US and other key markets have continued to move forward and are still ongoing at this time. In the context of these partnering discussions, it has suspended preparations for launching the product in the US on its own and minimized marketing and sales activities in Europe. Inner Ear Therapeutics On June 29, 2023, the FDA completed its review of Altamira’s IND application for AM-125 (betahistine nasal spray) in acute vestibular syndrome (AVS) and concluded that the proposed Phase 2 clinical trial with AM-125 in the treatment of posterior canal benign paroxysmal positional vertigo (BPPV), the most common type of vertigo, may proceed. The regulatory clearance opened the way for the clinical evaluation of AM-125 also in the United States. An earlier Phase 2 clinical trial conducted in Europe (the TRAVERS trial) demonstrated that a four-week treatment course with AM-125 in AVS patients, following surgical removal of a tumor behind the inner ear, was well tolerated and helped to accelerate vestibular compensation enabling patients to regain balance and recover faster. The new Phase 2 trial is designed to demonstrate AM-125’s tolerability and clinical utility also in BPPV. As previously announced, Altamira intends to divest or partner the AM-125 program for further development and commercialization in the context of its strategic pivot to RNA delivery technology. To this end, the Company has initiated discussions with a number of potential partners based on a structured approach. First Half 2023 Financial Results and Financial Guidance Revenues for the first half of 2023 were CHF 0.1 million compared to CHF 0.3 million for the first half of 2022, reflecting the waning of SARS-CoV-2 infections and, more importantly, the aforementioned strategic decision to temporarily reduce commercial activities around Bentrio® in anticipation of partnering transactions for key markets. Total operating loss for the first six months of 2023 was CHF 4.6 million compared with CHF 8.4 million for the first six months of 2022, a reduction of 45.5%. The improvement was primarily driven by lower expenditures for research and development (CHF 2.3 million vs. CHF 3.6 million) as clinical trials wound down, and for marketing and sales (CHF 0.2 million vs. CHF 2.1 million) as commercial activities were reduced. General and administrative expenses slightly increased in the first half of 2023 to CHF 2.2 million from CHF 2.1 million in the first half of 2022 as higher costs related to capital market projects outweighed reductions in administrative expenditures. Net loss for the first half of 2023 was CHF 5.4 million compared with CHF 8.2 million for the first half of 2022. Financial liabilities decreased from CHF 5.9 million at the end of 2022 to CHF 3.1 million at June 30, 2023. Shareholders’ equity improved at the same time from CHF -8.3 million to CHF -1.8 million. Cash and cash equivalents on June 30, 2023 totaled CHF 50 thousand compared with CHF 15 thousand at December 31, 2022. In early July 2023 Altamira raised $5.0 million in equity through the public offering of 11,111,112 common shares (or pre-funded warrants) at $0.45 each and 11,111,112 warrants with an exercise price of CHF 0.40 and a 5-year duration. The transaction yielded net proceeds of CHF 3.7 million. The Company expects its total cash need in 2023 to be in the range of CHF 12 to 14 million and in the 12 months from the issuance date of these financial statements to be in the range of CHF 12 to 14 million. First Half 2023 Investor Conference Call & Webcast Details Altamira management will hold an investor teleconference today, Tuesday, September 12, 2023, at 8:00 a.m. ET to discuss its business update and first half 2023 results. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. Event: Altamira Therapeutics First Half 2023 Financial Results and Business Update CallDate: Tuesday, September 12thTime: 8am ET (5am PT) Access: Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 500382Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/48993 Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available 30 minutes after the live call via the Investors section of the Altamira website at https://ir.altamiratherapeutics.com/. Replay Access:Toll Free replay number: 877-481-4010International: 919-882-2331Replay Passcode: 48993Expiration: September 26, 2023, 11:59 PM ET Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income or Loss (unaudited) For the Six Months Ended June 30, 2023 and 2022 (in CHF) SIX MONTHS ENDED JUNE 30 2023 2022 Revenue 105,469 290,798 Cost of Sales (212,181) (1,192,232)Gross profit (106,712) (901,434)Other operating income 111,405 255,820 Research and development (2,261,154) (3,563,883)Sales and marketing (160,936) (2,129,881)General and administrative (2,168,953) (2,076,383)Operating loss (4,586,350) (8,415,761)Finance expense (861,118) (377,985)Finance income 37,018 509,143 Loss before tax (5,410,450) (8,284,603)Income tax gain/(loss) (10,596) 46,085 Net loss attributable to owners of the Company (5,421,046) (8,238,518)Other comprehensive income: Items that will never be reclassified to profit or loss Remeasurement of defined benefit liability, net of taxes of CHF 0 (28,847) 209,526 Items that are or may be reclassified to profit or loss Foreign currency translation differences, net of taxes of CHF 0 137,747 (63,477)Other comprehensive income, net of taxes of CHF 0 108,900 146,049 Total comprehensive loss attributable to owners of the Company (5,312,146) (8,092,469) Condensed Consolidated Interim Statement of Financial Position (unaudited) As of June 30, 2023 and December 31, 2022 (in CHF) JUNE 30, DECEMBER 31, 2023 2022 ASSETS Non-current assets Property and equipment 1 1 Right-of-use assets 387,737 445,827 Intangible assets 3,893,681 3,893,681 Other non-current financial assets 192,958 194,263 Total non-current assets 4,474,377 4,533,772 Current assets Inventories 270,503 11,644 Trade receivables 31,813 6,525 Other receivables 756,234 755,987 Prepayments 374,376 709,266 Derivative financial instruments 247,090 270,176 Cash and cash equivalents 49,569 15,395 Total current assets 1,729,585 1,768,993 Total assets 6,203,962 6,302,765 EQUITY AND LIABILITIES Equity Share capital 1,590,801 236,011 Share premium 15,560,642 192,622,406 Other reserves 871,633 258,044 Accumulated deficit (19,847,641) (201,431,272)Total shareholders’ equity attributable to owners of the Company (1,824,565) (8,314,811) Non-current liabilities Loan 930,561 - Non-current lease liabilities 287,808 343,629 Employee benefits 381,362 336,206 Deferred income 932,200 932,200 Deferred tax liabilities 129,291 125,870 Total non-current liabilities 2,661,222 1,737,905 Current liabilities Loan 2,130,340 5,869,797 Current lease liabilities 118,229 117,856 Trade and other payables 1,964,139 4,914,404 Accrued expenses 1,154,598 1,977,614 Total current liabilities 5,367,305 12,879,671 Total liabilities 8,028,527 14,617,576 Total equity and liabilities 6,203,962 6,302,765 About Altamira TherapeuticsAltamira (Nasdaq: CYTO) is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore™ / SemaPhore™ delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The versatile delivery platform is also suited for mRNA and other types of RNA therapeutics and is planned to be leveraged via out-licensing to pharma or biotech companies. In addition, Altamira is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infection (Bentrio® OTC nasal spray; commercial) and inner ear therapeutics (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/ Forward-Looking StatementsThis press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of the continued commercialization of Bentrio and success of strategic transactions, including licensing or partnering, with respect to Bentrio or any other legacy assets, Altamira’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira’s product candidates, the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2022, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.